EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy

Ann E Metzloff iD, Marshall S Padilla, Ningqiang Gong, Margaret M Billingsley, Xuexiang Han, Maria Merolle, David Mai, Christian G Figueroa-Espada, Ajay S Thatte, Rebecca M Haley, Alvin J Mukalel, Alex G Hamilton und 5 weitere

Advanced Materials · 2024

DOI: 10.1002/adma.202313226 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, 2024. Verfasst von Ann E Metzloff und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA, 19104, USA. Hauptthemen laut MEDLINE: Nanoparticles, Receptors, Chimeric Antigen, Antigen-Presenting Cells, Immunotherapy, Adoptive. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, American Cancer Society Research Scholar Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable clinical success in the treatment of hematological malignancies. However, producing these bespoke cancer‐killing cells is a complicated ex vivo process involving leukapheresis, artificial T cell activation, and CAR construct introduction. The activation step requires the engagement of CD3/TCR and CD28 and is vital for T cell transfection and differentiation. Though antigen‐presenting cells (APCs) facilitate activation in vivo, ex vivo activation relies on antibodies against CD3 and CD28 conjugated to magnetic beads. While effective, this artificial activation adds to the complexity of CAR T cell production as the beads must be removed prior to clinical implementation. To overcome this challenge, this work develops activating lipid nanoparticles (aLNPs) that mimic APCs to combine the activation of magnetic beads and the transfection capabilities of LNPs. It is shown that aLNPs enable one‐step activation and transfection of primary human T cells with the resulting mRNA CAR T cells reducing tumor burden in a murine xenograft model, validating aLNPs as a promising platform for the rapid production of mRNA CAR T cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesReceptors, Chimeric AntigenAntigen-Presenting CellsImmunotherapy, AdoptiveT-LymphocytesRNA, MessengerHumansAnimalsMiceNeoplasmsImmunotherapyCell Line, TumorLipidsTransfectionLiposomes

Stichwörter der Autor:innen

CAR T cellsbiomimicrycancer immunotherapylipid nanoparticlesmRNA

Substanzen

Receptors, Chimeric AntigenRNA, MessengerLipid NanoparticlesLipidsLiposomes

Autor:innen und Institutionen

  • Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Department of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
  • Penn Institute for RNA Innovation, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.

ORCID-Profile: Ann E Metzloff, Michael J Mitchell

Förderung

  • NCI NIH HHS
  • NIDDK NIH HHS
  • American Cancer Society Research Scholar Grant
  • NIDCR NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS
  • University of Pennsylvania Fontaine Fellowship
  • Robert Wood Johnson Foundation Health Policy Research Scholars Program

Zitieren

APA

Metzloff, A. E., Padilla, M. S., Gong, N., Billingsley, M. M., Han, X., Merolle, M., Mai, D., Figueroa-Espada, C. G., Thatte, A. S., Haley, R. M., Mukalel, A. J., Hamilton, A. G., Alameh, M. G., Weissman, D., Sheppard, N. C., June, C. H., & Mitchell, M. J. (2024). Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202313226

Vancouver

Metzloff AE, Padilla MS, Gong N, Billingsley MM, Han X, Merolle M, et al. Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy. Advanced Materials. 2024. doi:10.1002/adma.202313226

BibTeX
@article{Metzloff2024,
  author = {Metzloff, Ann E and Padilla, Marshall S and Gong, Ningqiang and Billingsley, Margaret M and Han, Xuexiang and Merolle, Maria and Mai, David and Figueroa-Espada, Christian G and Thatte, Ajay S and Haley, Rebecca M and Mukalel, Alvin J and Hamilton, Alex G and Alameh, Mohamad-Gabriel and Weissman, Drew and Sheppard, Neil C and June, Carl H and Mitchell, Michael J},
  title = {Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy},
  journal = {Advanced Materials},
  year = {2024},
  doi = {10.1002/adma.202313226}
}
Kostenlos starten →